This selectivity profile is consistent with studies that have ascribed the efficacy of octreotide and lanreotide at inhibiting growth hormone release from somatotroph adenomas to their activity at sstr2 [39]. The gene discussed is SSTR2; the disease is growth hormone secreting pituitary adenoma 1.